Primary Open-Angle Glaucoma or Ocular Hypertension
Conditions
Interventions
At the begining of trial,one drop of glanatec solution 0.4% will be instilled to the subjective eye.
Sponsors
Kochi medical school hospital,ophthalmology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients over 20years old with Primary Open-Angle Glaucoma or Ocular Hypertension who are not well controlled by a ophthalmic solution,and need addional treatment. 2)Proir treatment must be plostaglandin(PG)formulations and/or beta-bookers and/or Acetazolamide,the prescription number of times is once a day. 3)Patients have never been treated with glanatec ophthalmic solution. 4)Agreement is proven by a document signed by patient.
Exclusion criteria
Exclusion criteria: 1)Patients having hypersensitivity against ripasujiru hydrochloride hydrate, Anhydrous dihydrogen phosphate sodium, Glycerine, Sodium hydroxide, Dark benzalconium chloride liquid 50. 2)Less than -12 dB of the MD value 3)Regarding pregnant women, Women whose terms are closed to and Lactating women, benefit is superior to dangerousness. 4)Secondary glaucoma, Exfoliation glaucoma,Angle closure glaucoma 5)Refract value: Less than-9.0D,More than +9.0D 6)Patients whose intra ocular pressure can not be measured by iCare Tonometer 7)Patients with traumatic injury. 8)Patients with ocular inflammation of anterior segment. 9)Patients who can not be applied for photo slit. 10)Patients having a history of the operation during the past 6 months. 11)Users of contact lenses 12)Patients who are decided not be suitable for this trial by doctors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary purpose of this study is to evaluate disappearing time-point of conjunctival hyperemia induced by glanatec ophthalmic solution 0.4% in patients with glaucoma.The evaluation is based on clinical scoring system. | — |
Secondary
| Measure | Time frame |
|---|---|
| Additionally,the relationship between decrease of intraocular pressure and conjunctival hyperemia will also be evaluated. Furthermore, by using conjunctival hyperemia analyzing software, evaluation of conjunctival hyperemia will be more objective. | — |
Countries
Japan
Contacts
Public ContactEmi Sakamoto
Kochi medical school hospital Ophthalmology
Outcome results
None listed